PF-Atlas › Clinical Trials › NCT02036580

D2212C00002 J-Phase II Study

tralokinumab cohort 1 · Phase 2

Registry ID
NCT02036580
Phase
Phase 2
Status
Completed
Drug / intervention
tralokinumab cohort 1
Sponsor
AstraZeneca
Start
2014-01
Enrollment
37
Locations
5

About this trial

The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.

View NCT02036580 on ClinicalTrials.gov →

Explore related

All tralokinumab cohort 1 trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02036580 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.